Search company, investor...

Proteologics

proteologics.com

Founded Year

1999

Stage

Series A | Alive

Total Raised

$17M

Last Raised

$17M | 21 yrs ago

About Proteologics

PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

Headquarters Location

40 Ramland Road South Suite 10

Orangeburg, New York, 10962,

United States

Missing: Proteologics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Proteologics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Proteologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Proteologics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Proteologics Patents

Proteologics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/7/2007

10/9/2012

Neurological disorders, Human proteins, Pyrimidinediones, Pyrimidines, Lactams

Grant

Application Date

11/7/2007

Grant Date

10/9/2012

Title

Related Topics

Neurological disorders, Human proteins, Pyrimidinediones, Pyrimidines, Lactams

Status

Grant

Proteologics Frequently Asked Questions (FAQ)

  • When was Proteologics founded?

    Proteologics was founded in 1999.

  • Where is Proteologics's headquarters?

    Proteologics's headquarters is located at 40 Ramland Road South, Orangeburg.

  • What is Proteologics's latest funding round?

    Proteologics's latest funding round is Series A.

  • How much did Proteologics raise?

    Proteologics raised a total of $17M.

  • Who are the investors of Proteologics?

    Investors of Proteologics include Giza Venture Capital, The Challenge Fund-Etgar, Deutsche Bank and Concord Ventures.

  • Who are Proteologics's competitors?

    Competitors of Proteologics include Inhibikase Therapeutics, Embera NeuroTherapeutics, Rigel Pharmaceuticals, Altor BioScience, Acetylon Pharmaceuticals and 11 more.

Compare Proteologics to Competitors

A
AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Topica Logo
Topica

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

Metabolic Solutions Logo
Metabolic Solutions

Metabolic Solutions is working with a compound in the same class of drugs as two well-known diabetes medications -- Actos and Avandia which combined for sales of more than $5 billion in 2007. The firm says a potential drug Metabolic Solutions is testing now could be safer and more effective than Actos and Avandia.

L
LaGray

LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.

A
Allostera

Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.